Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Invitae Corporation (NVTA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
5.37+0.86 (+19.07%)
At close: 04:00PM EDT
5.35 -0.02 (-0.37%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close4.51
Open4.47
Bid5.33 x 1400
Ask5.40 x 3000
Day's Range4.41 - 6.35
52 Week Range1.83 - 32.93
Volume152,152,597
Avg. Volume17,615,759
Market Cap1.263B
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-2.06
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NVTA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Invitae Corporation
    Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Motley Fool

    Is Soaring Invitae Stock a Smart Buy Now?

    Shares of Invitae (NYSE: NVTA) recently shot up like a rocket in response to a second-quarter earnings call that was a lot more positive than expected. Bringing comprehensive genetic information into mainstream medicine could make Invitae a top performer in the years ahead. Let's look a little closer at the company's performance this year to see if it's a smart stock to buy now and hold for the long run.

  • Motley Fool

    Why Invitae Corporation Stock Jumped 23% This Week

    Invitae Corporation (NYSE: NVTA), which specializes in medical genetic testing, saw its shares climb as high as 23% this week, according to data from S&P Global Intelligence. The stock closed at $2.30 last Friday, then opened on Monday at $2.37. The stock has been volatile with a 52-week low of $1.83 and a high of $32.93.

  • TipRanks

    What’s behind the Invitae stock roller coaster? Morgan Stanley weighs in

    Shares of San Francisco-based genetic testing and data company Invitae Corporation (NVTA) exploded higher after reporting earnings Tuesday night. After 6.5 trading hours on Wednesday, Invitae stock had nearly tripled in value before traders began cashing in some gains. In fact, on Thursday the stock has returned over half of yesterday’s gains, trading 47% lower. While investors were initially thrilled by the news, Morgan Stanley analyst Tejas Savant observed there were actually "no surprises" in

Advertisement
Advertisement